{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rhodes KR"],"funding":["National Institute of Allergy and Infectious Diseases","Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University","Troper Wojcicki Foundation","NIBIB NIH HHS","Johns Hopkins University","National Cancer Institute","NCI NIH HHS","NIGMS NIH HHS","National Institute of Biomedical Imaging and Bioengineering"],"pagination":["7913-7923"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8034558"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(7)"],"pubmed_abstract":["Biomimetic biomaterials are being actively explored in the context of cancer immunotherapy because of their ability to directly engage the immune system to generate antitumor responses. Unlike cellular therapies, biomaterial-based immunotherapies can be precisely engineered to exhibit defined characteristics including biodegradability, physical size, and tuned surface presentation of immunomodulatory signals. In particular, modulating the interface between the biomaterial surface and the target biological cell is key to enabling biological functions. Synthetic artificial antigen presenting cells (aAPCs) are promising as a cancer immunotherapy but are limited in clinical translation by the requirement of <i>ex vivo</i> cell manipulation and adoptive transfer of antigen-specific CD8+ T cells"],"journal":["ACS applied materials & interfaces"],"pubmed_title":["Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma."],"pmcid":["PMC8034558"],"funding_grant_id":["P41EB028239","R25 CA153952","AI072677","AI44129","R01 CA228133","R25CA153952","R01 EB029341","P41 EB028239","R33 CA229042","T32 CA153952","T32 GM007057","T32 CA130840","R01CA228133"],"pubmed_authors":["Hickey JW","Schneck JP","Green JJ","Ben-Akiva E","Rhodes KR","Meyer RA","Kosmides AK","Livingston NK","Isser A","Tzeng SY"],"additional_accession":[]},"is_claimable":false,"name":"Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.","description":"Biomimetic biomaterials are being actively explored in the context of cancer immunotherapy because of their ability to directly engage the immune system to generate antitumor responses. Unlike cellular therapies, biomaterial-based immunotherapies can be precisely engineered to exhibit defined characteristics including biodegradability, physical size, and tuned surface presentation of immunomodulatory signals. In particular, modulating the interface between the biomaterial surface and the target biological cell is key to enabling biological functions. Synthetic artificial antigen presenting cells (aAPCs) are promising as a cancer immunotherapy but are limited in clinical translation by the requirement of <i>ex vivo</i> cell manipulation and adoptive transfer of antigen-specific CD8+ T cells","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2025-04-04T10:17:09.317Z","creation":"2025-04-04T10:17:09.317Z"},"accession":"S-EPMC8034558","cross_references":{"pubmed":["33573372"],"doi":["10.1021/acsami.0c19955"]}}